Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.42 |
| ▸ | TP53 | P04637 | 6/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 8/20 | 0.42 |
| ▸ | RAB9A | P51151 | 8/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3614850 | 0.80 | NOTUM (0.56) | SMN1; SMN2NFKB1NFKB2RELANPC1 | |
| SCHEMBL1609658 | 0.75 | SMN1; SMN2 (0.41) | SMN1; SMN2TP53MAPK1KMT2AMEN1 | |
| SCHEMBL91494 | 0.75 | RAB9A (0.51) | SMN1; SMN2TP53MAPK1KMT2AMEN1 | |
| SCHEMBL15013375 | 0.72 | CASP3 (0.54) | SMN1; SMN2TP53MAPK1KMT2AMEN1 | |
| SCHEMBL77103 | 0.69 | RAB9A (0.51) | SMN1; SMN2TP53MAPK1KMT2AMEN1 | |
| SCHEMBL10247598 | 0.68 | RAB9A (0.46) | SMN1; SMN2TP53MAPK1KMT2AMEN1 | |
| SCHEMBL5660084 | 0.67 | RAB9A (0.56) | SMN1; SMN2TP53MAPK1KMT2AMEN1 | |
| SCHEMBL10867753 | 0.65 | KMT2A (0.46) | SMN1; SMN2MAPK1KMT2AMEN1RAB9A | |
| SCHEMBL512093 | 0.65 | NPC1 (0.41) | SMN1; SMN2TP53MAPK1KMT2AMEN1 | |
| SCHEMBL12171145 | 0.64 | CASP3 (0.67) | SMN1; SMN2TP53MAPK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086893-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LTD (GB) | 2011-04-14 | — | — | US | disclosed |
| US-20100035943-A1 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS (OXFORD) LTD (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20080227833-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LTD (GB) | 2008-09-18 | — | — | US | disclosed |
| US-7358265-B2 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS (R&D) LTD | 2008-04-15 | — | — | US | disclosed |
| EP-1476438-B1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS R&D LTD (GB) | 2007-04-18 | — | — | EP | disclosed |
| US-20050222189-A1 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS (OXFORD) LTD (GB) | 2005-10-06 | — | — | US | disclosed |
| WO-2004101537-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LTD (GB) | 2004-11-25 | — | — | WO | disclosed |
| EP-1476438-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | Vernalis (Oxford) Ltd (GB) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003070711-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LTD (GB) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222189-A1 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | MMP9, TIMP3, MMP13 | SMN1; SMN2 2499/4885TP53 3044/4885MAPK1 1679/4885 |
| US-20100035943-A1 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | MMP12, TIMP3, MMP9 | SMN1; SMN2 3288/4885TP53 4703/4885MAPK1 2030/4885 |
| US-20080227833-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | MMP12, TIMP3, MMP9 | SMN1; SMN2 3288/4885TP53 4703/4885MAPK1 2030/4885 |
| US-20110086893-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | MMP12, TIMP3, MMP9 | SMN1; SMN2 3288/4885TP53 4703/4885MAPK1 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.